Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

ALK-positive NSCLC Clinical Trial

Official title:
A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)

Status Active, not recruiting

Clinical Trial Summary

This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02393625
Study type	Interventional
Source	Novartis
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	May 27, 2015
Completion date	April 10, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05482087` - A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC	Phase 2
Recruiting	`NCT03804541` - The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human	Phase 1
Completed	`NCT04647110` - Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Recruiting	`NCT04009317` - Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)	Phase 3
Recruiting	`NCT04056572` - Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib	Phase 2